中国医学前沿杂志（电子版）Issue(2)：18-21,4.
吉西他滨联合奈达铂或卡铂一线治疗晚期非小细胞肺癌的疗效及安全性
Study of the efifcacy and toxicity of gemcitabine combined with nedaplatin versus gemcitabine or carbo platin as the ifrstline treatment in advanced nonsmall cell lung cancer
摘要
Abstract
Objective To evaluate the efifcacy and safety of gemcitabine in combination with nedaplatin/carboplatin against non-small cell lung cancer as the ifrst-line treatment. Method Retrospective analysed of our hospital from December 2011 to December 2013 received gemcitabine combined with nedaplatin (GN) or carboplatin (GC) in 39 patients with ifrst-line chemotherapy for advanced non-small cell lung cancer. Result Of all the 39 eligible patients, median progression free survival (PFS) was 4.0 months, and median OS was 12.0 months. GC group patients with disease remission rate (RR) was 33.3%, disease control rate (DCR) was 47.6%, PFS was 4 months, OS was 11 months, 6 months survival rate was 81%, 1 year survival rate was 47.6%;these indicators of GN group were 50%, 61.1%, 6 months, 12 months, 88.9%, 50%. The two groups of patients with hematologic toxicity and non hematologic toxicity compared the incidence had no signiifcant difference. GC group patients with the serious platelet reduce and severe anemia incidence were higher than that of GN group, but had no signiifcant differences (P>0.05). Conclusion Gemcitabine plus nedaplatin is non-inferior to gemcitabine plus carboplatin in terms of efifcacy and safety, which is a good choice as the ifrst-line treatment for advanced non-small cell lung cancer.关键词
晚期非小细胞肺癌/奈达铂/一线治疗/安全性Key words
Advanced non-small cell lung cancer/Nedaplatin/First-line treatment/Safety引用本文复制引用
姚舒洋,支修益,钱坤,胡牧,王若天,苏雷,刘宝东,李元博,许庆生,张毅..吉西他滨联合奈达铂或卡铂一线治疗晚期非小细胞肺癌的疗效及安全性[J].中国医学前沿杂志（电子版）,2015,(2):18-21,4.基金项目
首都医学发展科研基金 （）
